AmerisourceBergen Launches New Platform To Boost Patient Support Services

AmerisourceBergen Corporation (NYSE:ABC) announced the launch of its Cell and Gene Therapy (CGT) Integration Hub. This platform facilitates real-time data exchange to reduce potential barriers across the patient journey.
The platform allows physicians to expedite their investigation process with real-time visibility into therapy and treatment development.
Under the platform, AmerisourceBergen will offer support at each product lifecycle stage, including third-party logistics, regulatory consulting, and patient support services.
"Our goal is to increase connectivity and reduce potential barriers across the patient journey," said Dale Hanna, Director of Cell & Gene Therapy Solutions at AmerisourceBergen.
The company confirmed that it is on the verge of several landmark CGT approvals this year in the U.S., which reflects the rapid pace at which this sector is moving.
Also Read: AmerisourceBergen, TPG To Acquire OneOncology From General Atlantic For $2.1B
Price Action: ABC shares are up by 0.76% at $167.99 on the last check Monday.

To add Benzinga News as your preferred source on Google, click here.